DP
VKTX icon

Diadema Partners’s Viking Therapeutics VKTX Stock Holding History

Diadema Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-316,700
Closed -$11.1M – 207
2025
Q4 		$11.1M Buy
+316,700
New +$11.2M 1.92% 14

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Diadema Partners's VKTX Position: Q1 2026 in Review

Diadema Partners increased its Viking Therapeutics (VKTX) stake by 56% in Q1 2026, buying an estimated $6.05M and bringing the position to 525,181 shares worth $17.1M. The position accounts for 2.91% of the portfolio, ranked #8.

Diadema Partners first reported a position in VKTX in Q1 2025 and has held it in 5 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Diadema Partners held 525,181 shares of Viking Therapeutics worth $17.1M as of Q1 2026.
  • Diadema Partners bought 188,332 Viking Therapeutics shares in Q1 2026, an estimated $6.05M.
  • Viking Therapeutics made up 2.91% of Diadema Partners's portfolio in Q1 2026, its #8 holding.
  • Diadema Partners first reported a position in Viking Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.